Book a Meeting


Production of Therapeutic Cells

Cell surface engineering technologies have shown a strong potential to significantly improve the therapeutic efficacy of cells by controlling transport, tracking, engraftment, secretion, and cluster assembly of transplanted cells. As cell surface engineering has been playing such an important role in the production of therapeutic cells, to satisfy global customers’ demands, Creative Biolabs has launched high-quality cell surface conjugation services.

The Role of Cell Surface Engineering in Therapeutic Cells

Living cells are invaluable biomedical tools for the treatment and study of several incurable diseases, including cancer, metabolic disorders, and tissue defects. These diseases are particularly well-suited to cell-based therapies because they are difficult to treat with available drugs and surgical techniques. However, cell therapies have multiple hurdles to overcome before they can be widely adopted for clinical use. In this regard, one of the most important challenges is controlling transport, particularly for cells delivered systemically that are intended to treat multiple pathological sites in a noninvasive manner. Another key issue is that therapeutic cells delivered to injured or diseased tissues often lose viability and their therapeutic activity as a result of the hostile extracellular microenvironment. Additionally, cell therapies require controlling the cadherin-mediated cell-cell adhesion, which plays a major role in cellular differentiation. What these challenges mean practically is the need to use a large number of cells during transplantation. This leads to increased medical costs and ultimately to a less practical process. Toward this end, considerable effort has focused on modifying the cell surface to help regulate all aspects of the activity of therapeutic cells.

How Cell Surface Engineering Applied?

Controlling the Transport of Therapeutic cells

Controlling the transport of therapeutic cells following systemic transplantation is critical to improving the therapeutic efficacy, lowering the number of transplanted cells needed, and minimizing any undesirable side effects. One approach to achieving this aim is by mimicking the leukocyte recruitment or hematopoietic stem cell homing process.

Cell Tracking

Cell therapy typically involves the systemic infusion of living cells to exert a direct or indirect effect against human disease. The efficacy of cell therapy can be improved by facilitating migration toward the target tissues. Thus, tracking the transport and destination of cells systemically or locally injected into a body is necessary to ascertain their homing and engraftment. Bioimaging approaches are the most common way, and labeling cells with a series of molecules or nanoparticles can increase imaging sensitivity.

Cell Engraftment

Cell engraftment is another important factor to consider for the successful application of cell therapy. To support the engraftment of transplanted cells to the target tissue, reducing the immune response and neutralizing the oxidative environment is crucial. These purposes prompted a series of cell surface engineering techniques that can extend the period in which transplanted cells remain therapeutically active.

Schematic illustration of the leukocyte transmigration process. Fig.1 Schematic illustration of the leukocyte transmigration process. (Park, 2018)

Services at Creative Biolabs

Creative Biolabs has been focusing on cell-surface engineering for years, thus we have accumulated a lot of experience and become professional in providing cell-surface conjugation services. The scope of our technical services covers:

Committed to cell surface engineering research for years, Creative Biolabs has become a professional cell surface engineering services provider with a great industrial reputation. If you are interested in cell surface conjugation services, please don’t hesitate to contact us for more information.


  1. Park, J.; et al. Engineering the surface of therapeutic "living" cells. Chem Rev. 2018, 118(4): 1664-1690.

All services are only provided for research purposes and Not for clinical use.

  • *
  • *
  • *

United Kingdom